Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Alisa Heuser, Wassim Abdul Rahman, Elisabeth Bechter, Jutta Blank, Sylvia Buhr, Dirk Erdmann, Patrizia Fontana, Fanny Mermet‐Meillon, Marco Meyerhofer, Ross Strang, Maxime Schrapp, Catherine Zimmermann, Marta Cortes‐Cros, Henrik Möbitz, Jacques Hamon
Natura: Artículo Open Access
Pubblicazione: Wiley 2024
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867019465217015808
author Alisa Heuser
Wassim Abdul Rahman
Elisabeth Bechter
Jutta Blank
Sylvia Buhr
Dirk Erdmann
Patrizia Fontana
Fanny Mermet‐Meillon
Marco Meyerhofer
Ross Strang
Maxime Schrapp
Catherine Zimmermann
Marta Cortes‐Cros
Henrik Möbitz
Jacques Hamon
author_facet Alisa Heuser
Wassim Abdul Rahman
Elisabeth Bechter
Jutta Blank
Sylvia Buhr
Dirk Erdmann
Patrizia Fontana
Fanny Mermet‐Meillon
Marco Meyerhofer
Ross Strang
Maxime Schrapp
Catherine Zimmermann
Marta Cortes‐Cros
Henrik Möbitz
Jacques Hamon
Alisa Heuser
Wassim Abdul Rahman
Elisabeth Bechter
Jutta Blank
Sylvia Buhr
Dirk Erdmann
Patrizia Fontana
Fanny Mermet‐Meillon
Marco Meyerhofer
Ross Strang
Maxime Schrapp
Catherine Zimmermann
Marta Cortes‐Cros
Henrik Möbitz
Jacques Hamon
collection Wiley Open Access
contents Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors Alisa Heuser Wassim Abdul Rahman Elisabeth Bechter Jutta Blank Sylvia Buhr Dirk Erdmann Patrizia Fontana Fanny Mermet‐Meillon Marco Meyerhofer Ross Strang Maxime Schrapp Catherine Zimmermann Marta Cortes‐Cros Henrik Möbitz Jacques Hamon ChemMedChem AbstractThe Werner Syndrome RecQ helicase (WRN) is a synthetic lethal target of interest for the treatment of cancers with microsatellite instability (MSI). Different hit finding approaches were initially tested. The identification of WRN inhibitors proved challenging due to a high propensity for artefacts via protein interference, i. e., hits inhibiting WRN enzymatic activities through multiple, unspecific mechanisms. Previously published WRN Helicase inhibitors (ML216, NSC19630 or NSC617145) were characterized in an extensive set of biochemical and biophysical assays and could be ruled out as specific WRN helicase probes. More innovative screening strategies need to be developed for successful drug discovery of non‐covalent WRN helicase inhibitors. 10.1002/cmdc.202300613 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/cmdc.202300613
format Artículo Open Access
id wiley_oa_10_1002_cmdc_202300613
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors
Alisa Heuser
Wassim Abdul Rahman
Elisabeth Bechter
Jutta Blank
Sylvia Buhr
Dirk Erdmann
Patrizia Fontana
Fanny Mermet‐Meillon
Marco Meyerhofer
Ross Strang
Maxime Schrapp
Catherine Zimmermann
Marta Cortes‐Cros
Henrik Möbitz
Jacques Hamon
ChemMedChem
Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors Alisa Heuser Wassim Abdul Rahman Elisabeth Bechter Jutta Blank Sylvia Buhr Dirk Erdmann Patrizia Fontana Fanny Mermet‐Meillon Marco Meyerhofer Ross Strang Maxime Schrapp Catherine Zimmermann Marta Cortes‐Cros Henrik Möbitz Jacques Hamon ChemMedChem AbstractThe Werner Syndrome RecQ helicase (WRN) is a synthetic lethal target of interest for the treatment of cancers with microsatellite instability (MSI). Different hit finding approaches were initially tested. The identification of WRN inhibitors proved challenging due to a high propensity for artefacts via protein interference, i. e., hits inhibiting WRN enzymatic activities through multiple, unspecific mechanisms. Previously published WRN Helicase inhibitors (ML216, NSC19630 or NSC617145) were characterized in an extensive set of biochemical and biophysical assays and could be ruled out as specific WRN helicase probes. More innovative screening strategies need to be developed for successful drug discovery of non‐covalent WRN helicase inhibitors. 10.1002/cmdc.202300613 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors
topic ChemMedChem
url https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202300613